Brief: Neuren Pharmaceuticals Says Trofinetide New Drug Submission For Rett Syndrome Accepted For Priority Review By Health Canada
23/04/2024 02:22
April 23 (Reuters) - Neuren Pharmaceuticals Ltd
NEU.AX :
* TROFINETIDE NEW DRUG SUBMISSION FOR RETT SYNDROME ACCEPTED
FOR
PRIORITY REVIEW BY HEALTH CANADA
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union